632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Mechanisms of resistance and expanded therapies
Michael W. Deininger, Jane F Apperley, Christopher Kevin Arthur, et al.
Xiaoshuai Zhang, Zongru Li, Yazhen Qin, et al.
The use of the 3rd generation TKI therapy achieves a poor response to ASXL1 mutations with a VAF ≥ 17% and PHF6 mutations. There were also worse results with STAT5A and RUNX1 mutations as well as high-risk ACAs.
Jorge E. Cortes, Tapan Saikia, Dong-Wook Kim, et al.
Vodobatinib in patients with heavily previously treated CML who failed ≥ 3 previous TKIs, including ponatinib, remains beneficial with a long-term safety and efficacy.
Michael J. Mauro, Yosuke Minami, Delphine Rea, et al.
After a median follow-up time of 19.2 months, the study authors assume a positive benefit-risk profile of asciminib compared to BOS and recommend the use of asciminib as a new therapy in this heavily pretreated patient population.
Jiang Qian, Dayu Shi, Zongru Li, et al.
According to the study authors, olverembatinib is efficacious and well tolerated in TKI-resistant CML-CP or CML-AP and long-term treatment.
Mhairi Copland, Daniel Slade,Graham McIlroy, et al.
Ponatinib can be safely combined with high-dose chemotherapy to bring about a return to the chronic phase in patients with BP-CML, making ponatinib an effective new treatment strategy for these high-risk patients. Patients who respond to therapy and who then undergo alloSCT can benefit from long-term disease-free survival.